NEW study for ages 9 years and older. 3-week oral antibiotic study for back and/or chest acne. At least 20 lesions are required. Photographs will be taken.
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE ACNE STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339
NEW study for adults 18 years and older with a diagnosis of psoriasis. Must have history of at least 6 months on Consyntex or Talz. No prior use of Skyrizi. No investigational drug use within 30 days. No major surgeries within 12 weeks, or major planned surgeries. You are being asked whether you would like to voluntarily participate in a research study of a drug called risankizumab (SkyriziTM).
This research study involves the use of an approved drug called risankizumab (SkyriziTM) to treat moderate to severe psoriasis. This study is being run in approximately 50 research centers in 9 countries and is expected to enroll approximately 250 subjects.
If you decide to participate, you will be in this study for up to 64 weeks. The study comprises 3 periods: There will be a 30-day Screening Period, a 52-week open-label study period and a 20-week follow-up period following the last dose of study drug scheduled at Week 40 visit (weeks 40-52 of the open-label period will also be weeks 1-12 of the follow-up period). The open-label period means that you, your study doctor and AbbVie know that what study treatment you are receiving.
You may need to come in for additional (unscheduled) visits if necessary, as determined by your study doctor. If you are eligible to receive study treatment, you will receive 2 injections of active risankizumab 75 mg (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4 visits, and then every 12 weeks (q12w) until the last dose at Week 40 visit. At any time, you may choose to discontinue from the study and end study participation early, or your study doctor may discontinue your participation for any reason at any time.
AbbVie is sponsoring this study. Being in this study does not replace your regular medical care. AbbVie may stop this study prematurely, either in its entirety or at any study site, for reasonable cause, provided that written notice is submitted in advance of the intended study stop.
Arlington Research Center is looking for children and adults, aged 6 years and up who have eczema, to participate in a clinical research study evaluating an investigational cream. This study includes up to 5 visits for 2 months.
Studies for youth and adults. Must have a history of atopic for at least 3 months for youth 6-17 years of age, and for at least 6 months for adults 18 years and older. Study patients previously on the ARQ-151 are excluded.
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE INTEGUMENT STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339
NEW study for adults 18 and older. Topical cream and at-home phototherapy system. Must have facial vitiligo. Subjects with vitiligo on the hands, forearms, or elbows may treat areas in addition to the face with the cream. Begins in mid-March.
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE VITILIGO STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339
We know life with Hidradenitis Suppurativa isn’t always easy.
There are many unanswered questions surrounding the causes of HS and the painful and distressing symptoms it triggers in the body. With limited approved medical treatment options available, it’s important to keep looking for potential answers.
For this reason, the Ivy Clinical Research Study is investigating 3 different possible treatment options to assess the benefits each could offer to people with moderate to severe HS.
The Ivy Study may be an option for you if:*
*There are other requirements for participation in the study. The study doctor will be able to explain these to you.
Youth ages 6-17 years old may qualify for this new study.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in any of these upcoming Clinical Trials.
COMING SOON!!!
New study for ages 12-45 years old. 20 to 100 inflammatory lesions. No more than 2 facial inflammatory nodules or cysts and a minimum of 10 non-inflammatory facial lesion.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
COMING SOON!!!
No more than 5 nodules. At least mild facial erythema and mild telangiectasia. For adults aged 18 years and older. Must not have rhinophyma, dense telangiectasia, plaque-like edema, or ocular rosacea. Must not have atopic dermatitis, perioral dermatitis, or seborrheic dermatitis.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
COMING SOON!!
New study for ages 2 years old and up. No more than 6 warts present at screening/baseline visit. Warts must have been present for 4 weeks.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
Youth ages 12-18 years old may qualify for this new Chronic Plaque Psoriasis study.
Study focuses on how a drug called Risankizumab may help children with moderate to severe psoriasis. Psoriasis is a condition in which skin cells build up and form red, itchy, scaly patches. Risankizumab is approved for use in adults however, it has been not been approved for children in the United States and other countries, and we want to learn more about how it works. This is called a “research study.” This is the first study where the study drug will be tested in children.
If you decide to be in the research study, you will be asked to take part in this study for about 65 weeks and this may include 9 study visits and 1 follow-up phone call. You will receive a risankizumab injection every 12 weeks after the week 4 visit.
You will need your parent’s approval to participate in this study if you are younger than 18.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
